Serdemetan NEW
| Price | $39 | $64 | $97 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Serdemetan | CAS No.: 881202-45-5 |
| Purity: 98.18% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Serdemetan |
| Description | Serdemetan (JNJ-26854165) is an orally bioavailable HDM2 antagonist with potential antineoplastic activity. |
| Cell Research | Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK(Only for Reference) |
| In vitro | In both solid and ALL transplant tumor models, oral administration of JNJ-26854165 (20 mg/kg) significantly altered EFS distribution. |
| In vivo | In leukemia cell lines, JNJ-26854165 inhibits cell growth and induces apoptosis, demonstrating inhibitory effects on OCI-AML-3 (IC50=0.24 μM), MOLM-13 (IC50=0.33 μM), NALM-6 (IC50=0.32 μM), and REH (IC50=0.44 μM). Additionally, it inhibits cell proliferation in various human cancer cell lines (H460, A549, p53-WT-HCT116, and p53-null-HCT116). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 2 mg/mL (6.08 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 50 mg/mL (152.25 mM), Sonication is recommended. |
| Keywords | E3 ligating enzyme | E1/E2/E3 Enzyme | Ubiquitin activating enzyme | E1 activating enzyme | Ubiquitin ligase | Inhibitor | JNJ26854165 | E2 conjugating enzyme | JNJ 26854165 | inhibit | Ubiquitin conjugating enzyme | MDM-2/p53 | Serdemetan | Apoptosis |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Lidocaine hydrochloride |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.10/1g |
VIP4Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2021-05-12 | |
| $5.00/5KG |
VIP7Y
|
Career Henan Chemical Co
|
2019-09-03 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY